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Infl  ammatory bowel diseases (IBDs), such as 
ulcerative colitis (UC) and Crohn’s disease, 
are well known to increase the risk of devel-
oping colorectal cancer. Indeed, IBDs rank 
among the top three high-risk conditions for 
colorectal cancer, together with familial ade-
nomatous polyposis and hereditary nonpolyp-
osis colorectal cancer (1). Epidemiological studies 
have indicated that regular administration of 
nonsteroidal antiinfl   ammatory drugs lowers 
mortality from sporadic colorectal cancer and 
causes regression of adenomas in patients with 
familial adenomatous polyposis (2). Recently, 
the NF-κB pathway is shown to be one of the 
key molecular mechanisms for   developing 
  infl  ammation-  related cancer (3, 4). The role 
of other proinfl   ammatory signal pathways 
  remains unknown.
The JAK/STAT pathway is another major 
signaling pathway for modulating pro- and 
antiinfl  ammatory responses. It is also closely 
correlated with IBDs, since UC and Crohn’s 
disease are associated with a predominance 
of IFNγ-producing T helper (Th)1 cells and 
IL-4 producing Th2 cells, respectively (5). 
Suppressor of cytokine signaling-1 (SOCS1) is 
an intracellular protein that inhibits JAK-
  mediated cytokine signaling by binding to 
JAKs (6). SOCS1 has been shown to be an 
important physiological negative regulator of 
various cytokines including IFNγ and IL-4. 
SOCS1 also modulates toll-like receptor (TLR) 
signaling in macrophages (7). SOCS1-defi  cient 
mice (SOCS1−/−) die neonatally because 
of multiorgan infl   ammation (6). We also 
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Approximately 20% of human cancers are estimated to develop from chronic infl  ammation. 
Recently, the NF-𝗋B pathway was shown to play an essential role in promoting infl  amma-
tion-associated cancer, but the role of the JAK/STAT pathway, another important signaling 
pathway of proinfl  ammatory cytokines, remains to be investigated. Suppressor of cytokine 
signaling-1 (SOCS1) acts as an important physiological regulator of cytokine responses, and 
silencing of the SOCS1 gene by DNA methylation has been found in several human cancers. 
Here, we demonstrated that SOCS1-defi  cient mice (SOCS1−/−Tg mice), in which SOCS1 
expression was restored in T and B cells on a SOCS1−/− background, spontaneously devel-
oped colorectal carcinomas carrying nuclear 𝗃-catenin accumulation and p53 mutations at 
6 months of age. However, interferon (IFN)𝗄−/−SOCS1−/− mice and SOCS1−/−Tg mice treated 
with anti-IFN𝗄 antibody did not develop such tumors. STAT3 and NF-𝗋B activation was 
evident in SOCS1−/−Tg mice, but these were not suffi  cient for tumor development because 
these are also activated in IFN𝗄−/−SOCS1−/− mice. However, colons of SOCS1−/−Tg mice, 
but not IFN𝗄−/−SOCS1−/− mice, showed hyperactivation of STAT1, which resulted in the 
induction of carcinogenesis-related enzymes, cyclooxygenase-2 and inducible nitric oxide 
synthase. These data strongly suggest that SOCS1 is a unique antioncogene which prevents 
chronic infl  ammation-mediated carcinogenesis by regulation of the IFN𝗄/STAT1 pathways.
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  reported that SOCS1−/−TCRα−/− mice develop very 
  severe colitis within 9 wk of age which resembles human 
UC (8). Development of this colitis was dependent on 
both IFNγ and IL-4. Thus, SOCS1 is an important nega-
tive regulator of infl   ammation by limiting cytokine and 
TLR signaling.
SOCS1 has also been suggested to function as an antion-
cogene. Mutations and deletions of the SOCS1 gene have 
been found in several lymphomas (9). Yoshikawa et al. re-
ported that aberrant methylation in the CpG island of SOCS1 
was correlated with transcriptional silencing of the SOCS1 
gene in hepatocellular carcinoma (10). Moreover, restoration 
of SOCS1 suppressed both the growth rate and the anchor-
age-independent growth of the cells in which SOCS1 was 
methylation silenced. In addition, SOCS1 methylation has 
also been reported in various types of human cancers, includ-
ing colorectal cancer (11, 12). Experimentally, Rottapel et al. 
and our group showed that SOCS1-defi  cient fi  broblasts were 
more sensitive to both spontaneous and oncogenes (v-ABL, 
p210 BCR-ABL, 70Z/3 CBL, and papilloma virus E7)-
  induced transformation than wild-type fi  broblasts (13, 14). 
Furthermore, we demonstrated that carcinogen-induced 
  hepatocellular carcinoma development was enhanced in 
SOCS1+/− mice, indicating that SOCS1 functions as an an-
tioncogene in vivo (15). Interestingly, we found that SOCS1 
gene silencing by DNA methylation is frequently observed in 
the pretransformed liver infected with human hepatitis C 
  virus (15). SOCS1 gene methylation was well correlated 
with the severity of liver fi  brosis, suggesting that reduction of 
SOCS1 gene expression promotes liver infl  ammation. These 
fi  ndings suggest that SOCS1 is a unique antioncogne that 
prevents infl  ammation-associated carcinogenesis. However, 
the precise molecular function of SOCS1 in cancer develop-
ment is unknown.
Figure 1.  Colorectal tumors in SOCS1−/−Tg mice. (A) Percentage of 
histologically determined colitis (red circle) and tumor (black circle) inci-
dence in SOCS1−/−Tg mice. (B) Macroscopic view of colon tumors in 
SOCS1−/−Tg mice. Arrows indicate tumors. (C–L) HE-stained sections of 
colitis and grades of dysplasia and neoplasia in SOCS1−/−Tg mice. The top 
and bottom panels in each row show medium- and high-magnifi  cation 
views of the mucosa, respectively. (C and D) Histology of a wild-type con-
trol mouse. (E and F) Colitis, indefi  nite for dysplasia in SOCS1−/−Tg mice. 
(G and H) Mildly active cryptitis with neutrophilic infi  ltration and goblet 
cell depletion are evident. The nuclei are mildly swollen but uniform in 
size and shape. Epithelial maturation toward the surface is preserved. 
(G and H) Low-grade dysplasia with villous confi  guration in SOCS1−/−Tg 
mice. The crypts are uniformly lined with tall epithelial cells containing 
mildly elongated and hyperchromatic nuclei. (I and J) Colitis with high-
grade dysplasia in SOCS1−/−Tg mice. Eroded and infl  amed mucosa with 
cryptoabscesses can be seen. In addition, the tubuli show an irregular 
arrangement and budding. The nuclei are elongated, hyperchromatic, and 
pseudostratifi  ed. (K and L) High-grade dysplasia and intramucosal carci-
noma in SOCS1−/−Tg mice. The desmoplastic stroma has assumed early 
invasive growth. Bars: (C, E, G, I, K) 200 μm; (D, F, H, J, I) 50 μm. 
(M) Immunohistochemical staining for β-catenin, total p53 (CM1), and 
mutant p53 (CM5) in colon tumors from SOCS1−/−Tg mice and WT 
  littermates. Bars, 50 μm.JEM VOL. 203, June 12, 2006  1393
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RESULTS AND DISCUSSION
SOCS1−/−Tg mice spontaneously develop colon cancer
SOCS1−/−Tg mice, in which exogenous SOCS1 is only 
  expressed in T and B cells, survived for more than 1 yr (16). 
However, typical colitis, including hyperplasia of the crypt 
epithelium, the loss of goblet cells, crypt abscess formation, 
and mixed infl   ammatory cellular infi  ltration in the lamina 
propria mucosa, were observed in SOCS1−/−Tg mice after 3 
mo of age (Fig. 1 A). In addition, we discovered frequent de-
velopment of colon tumors in SOCS1−/−Tg mice after 6 mo 
of age. The frequency of colon tumors in these mice increased 
as the mice became older (Fig. 1 A). Most of the tumors in 
SOCS1−/−Tg mice occurred in the proximal parts of the co-
lon, similar to human colitis-associated colorectal cancers (1) 
(Fig. 1 B). Histologically, these colon tumors were developed 
from dysplastic epitherial cells at infl  ammation sites (Fig.1, 
C–L). Regenerative mucosa and low- to moderate-grade 
dysplasia, which are found at high frequency in human UC, 
were also detected in the colon of SOCS1−/−Tg mice (Fig. 1, 
E–J). β-catenin gene mutations and accumulation of this pro-
tein in the nucleus are very important events in colorectal 
carcinogenesis (17). As expected, strong β-catenin expression 
was seen in the nucleus and cytoplasm of adenocarcinoma 
cells in the immunohistochemical staining (Fig. 1 M). Fur-
thermore, p53 staining using two rabbit polyclonal   antibodies 
(CM1 specifi  c for both wild-type and   mutant p53 proteins 
and CM5 specifi  c for the mutant p53 protein)   revealed the 
accumulation of mutant p53 proteins in the nuclei of tumor 
cells (Fig. 1 M). These results suggest that SOCS1 defi  ciency 
is related to colon tumor initiation nd/or promotion.
Colitis and colon tumor development is dependent on IFN𝗄 
but not TNF𝗂 in SOCS1−/−Tg mice
As shown in Fig. 1 A, colitis was ahead of the development of 
colon tumors. Although IFNγ−/−SOCS1−/− mice survived 
for more than 1 yr, they did not develop strong colitis and 
any colon tumors, suggesting that IFNγ plays an essential role 
in tumorigenesis. Therefore, we examined the eff  ect of the 
depletion of IFNγ by anti-IFNγ antibody treatment. We also 
compared the eff  ect of anti-TNFα antibody because TNFα 
has been suggested to play an important role in hepatocellular 
carcinoma developed in Mdr2-defi  cient mice (4). As shown 
in Fig. 2 (A and B), anti-IFNγ antibody, but not anti-TNFα 
antibody, blocked colitis as well as colon tumor development 
Figure 2.  Anti-IFN𝗄 mAb but not anti-TNF𝗂 mAb treatment ame-
liorated the colitis and colon tumor development in SOCS1−/−Tg 
mice. SOCS1−/−Tg mice at 2 mo of age were treated either with control IgG, 
anti-IFNγ, or anti-TNFα mAb for 4 mo. The colitis score (A) and tumor inci-
dence (B) are shown. (C) The representative HE staining of the colonic sec-
tions from the SOCS1−/−Tg mice after antibody treatment. Bars, 100 μm.
Figure 3.  Activation of STAT1, STAT3, and NF-𝗋B in SOCS1−/−Tg 
colons. (A) Western blot analysis of whole colon samples from indicated 
mice were performed with the indicated antibodies. The data are repre-
sentative of three independent experiments each experiment using two 
mice per group. (B) Immunostaining for phospho-STAT1, phospho-STAT3, 
and NF-κB (p65) in the colons of SOCS1+/+Tg and SOCS1−/−Tg mice. 
Arrows indicate nuclear accumulation of p65. Bars, 50 μm. 1394  COLORECTAL TUMORIGENESIS IN SOCS1−/− MIC | Hanada et al. 
in SOCS1−/−Tg mice. Failure of the suppression of colitis 
by anti-TNFα antibody was also   observed in SOCS1−/−
TCRα−/− mice (8), suggesting that colitis developed by 
SOCS1 defi  ciency does not depend on TNFα. Colitis found 
in SOCS1−/−Tg mice resembled that of SOCS1−/−TCRα−/− 
mice (8), but much less severe than that of SOCS1−/−
TCRα−/− mice, and all SOCS1−/−TCRα−/− mice died by 
20 wk of age. Thus, chronic infl  ammation for certain period 
seems to be necessary for the development of tumors.
Hyperactivation of STAT1, STAT3, and NF-𝗋B in colons 
of SOCS1-defi  ceint mice
It has been demonstrated that transcription factors STAT1, 
STAT3, and NF-κB were activated in the colon of human 
IBD and in mouse colitis models. Therefore, we examined the 
activation status of these transcription factors in SOCS1−/−Tg 
mice by Western blotting (Fig. 3 A). NF-κB activation was 
assessed by the phosphorylation of inhibitor of NF-κB (IκB). 
Low levels of activation of STAT1, STAT3, and NF-κB 
were detectable in WT and IFNγ−/− mice. On the other 
hand, constitutive STAT3 activation and IκB phosphory-
lation was seen in the colons of both SOCS1−/−Tg and 
IFNγ−/−SOCS1−/− mice (Fig. 3 A). These data suggest that 
SOCS1 may regulate STAT3 and NF-κB activations in   colon 
cells even in the absence of IFNγ. However, strong STAT1 
activation was observed in the colon of SOCS1−/−Tg mice, 
but not in IFNγ−/−SOCS1−/− mice. Thus, constitutive 
activation of STAT1 signaling appears to depend on IFNγ 
and to be necessary for tumor development.
Next, we examined in which cells these transcription 
  factors are activated by the immunohistochemical staining 
(Fig. 3 B). Immunoreactivities for phosphorylated STAT1 
and STAT3 were found in the nuclei of both normal epithe-
rial cells and tumor cells in SOCS1−/−Tg colon. Low levels 
Figure 4.  Expression of tumorigenic factors in SOCS1-defi  cient 
colons. (A) Immunostaining for PCNA and TUNEL staining in the colons 
of SOCS1+/+Tg and SOCS1−/−Tg mice at 6 mo of age.  Bars, 50 μm. The 
average numbers of PCNA-positive cells and TUNEL-positive cells per one 
side of the colonic crypts are indicated in the bar graph. Error bars repre-
sent ± SE. *, P < 0.05 compared with SOCS1+/+Tg mice. White bars, 
SOCS1+/+Tg; gray bars, SOCS1−/−Tg nontumor; black bars,  SOCS1−/−Tg 
tumor. (B) Western blot analysis of the Bcl-xL, c-Myc, iNOS, COX-2, and 
STAT5 levels in whole colonic extracts from indicated mice. (C) Immuno-
staining for iNOS, COX-2, and F4/80. Bars, 50 μm. (D) Western blot analysis 
of the COX-2 and iNOS expression in response to IFNγ in the macro-
phages from SOCS1+/+Tg and SOCS1−/−Tg mice and MEFs from WT and 
SOCS1−/− mice.JEM VOL. 203, June 12, 2006  1395
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of STAT activation were detected in infi  ltrated mononuclear 
cells. Nuclear accumulation of p65 subunit of NF-κB was 
observed in epitherial cells in nontumor regions and 
in tumor cells in SOCS1−/−Tg mice but not in WT mice 
(Fig. 3 B). High levels of extracellular signal-regulated kinase 
activation were observed in both normal and tumor epithe-
rial cells, but not in mononuclar cells in SOCS1−/−Tg mice 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20060436/DC1).
To defi   ne the molecular basis of STAT3 and NF-κB 
  activation in SOCS1-defi  cient colons, we analyzed the mRNA 
expression levels of IL-1β, IL-6, and TNFα. Although 
IL-1β and IL-6 were not elevated in SOCS1−/− colons, 
TNFα expression was signifi  cantly higher (P < 0.05) in both 
IFNγ−/−SOCS1−/− and SOCS1−/−Tg mice than in their 
control IFNγ−/− and SOCS1+/+Tg mice, respectively (Figs. 
S1 and S2, available at http://www.jem.org/cgi/content/
full/jem.20060436/DC1). TNFα expression was observed 
in infi  ltrated mononuclear cells in both tumor and nontumor 
regions in SOCS1−/−Tg mice (Fig. S1). This may account 
for constitutive activation of NF-κB signaling observed 
in SOCS1−/−Tg colons (Fig. 3, A and B). However, because 
IL-6 was not up-regulated in SOCS1-defi  cient    colons, 
the cytokines responsible for the STAT3 hyperacti  vation 
  remain unclear.
Factors that are involved in tumorigenesis 
in SOCS1-defi  cient colons
To address the proliferative states of the colonic crypts of 
SOCS1+/+Tg and SOCS1−/−Tg mice, we performed 
PCNA staining in these mice at 6 mo of age. The numbers 
of proliferating cells stained with anti-PCNA antibody were 
increased not only in the tumor areas but also in nontumor 
areas of SOCS1−/−Tg mice compared with SOCS1+/+Tg 
mice (Fig. 4 A). These data demonstrate that proliferation of 
the intestinal epithelium are augmented in SOCS1−/−Tg 
mice, even in nontumor areas. To examine the state of epi-
thelial apoptosis, the terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling (TUNEL) assay was 
performed. TUNEL-positive cells were seen in the surface epi-
thelium of the colon in both SOCS1+/+Tg and SOCS1−/−Tg 
mice, and there was no substantial diff  erence in the number 
of apoptotic cells between these mice. On the other hand, 
TUNEL-positive cells were signifi  cantly decreased (P < 0.05) 
in the tumor areas of the colon in SOCS1−/−Tg mice 
(Fig. 4 A). These results indicate that the apoptotic balance 
is disrupted at sites showing tumorigenic transformation of 
the intestinal epithelium in SOCS1−/−Tg mice, but normal 
in nontumor areas.
Then, we investigated the target genes of activated STATs 
and NF-κB. STAT3 has been proposed to participate in on-
cogenesis through up-regulation of genes such as apoptosis 
inhibitors (Bcl-xL, Mcl) and cell cycle regulators (c-Myc, cy-
clins D1/D2) (18). Greten et al. also demonstrated that IKKβ 
acts by suppressing the mitochondrial apoptosis pathway 
through induction of the NF-κB target gene Bcl-xL in a 
DSS/AOM colon cancer model (3). Up-regulation of Bcl-xL 
and cell cycle regulators during tumor promotion appears 
to be important in colorectal cancer development (19). 
As expected, the expression levels of Bcl-xL and c-Myc were 
up-regulated in SOCS1−/−Tg mice (Fig. 4 B).
However, regardless of the up-regulations of Bcl-xL and 
c-Myc (Fig. 4 B), IFNγ−/−SOCS1−/− mice did not develop 
any colon tumors, suggesting that IFNγ/STAT1-specifi  c 
molecules may be essential for tumor initiation. We exam-
ined inducible nitric oxide synthase (iNOS) and cyclooxy-
genase (COX)-2, which are induced by IFNγ (20, 21) are 
thought to be crucial for infl  ammation-mediated colon carci-
nogenesis (22, 23). The expression levels of iNOS and COX-
2 were considerably higher in SOCS1−/−Tg colons than in 
IFNγ−/−SOCS1−/− colons, and these levels were in parallel 
with the STAT1 phosphorylation (Fig. 4, B and C). Immuno-
histochemical staining revealed that COX-2 was strongly 
  expressed in macrophages in nontumor areas of SOCS1−/−Tg 
mice compared with SOCS1+/+Tg mice (Fig. 4 C). In the 
tumor areas of SOCS1−/−Tg mice, COX-2 was detected 
in both tumor cells and macrophages. iNOS was also 
strongly detected in macrophages in both nontumor and 
  tumor areas, but weakly detected in tumor cells (Fig. 4 C). 
Therefore, activated macrophages may be the main producer 
of iNOS in the colon of SOCS1−/−Tg mice. The numbers 
of macrophages infi  ltrated the colon were much higher in 
SOCS1−/−Tg mice than in SOCS1+/+Tg mice (Fig. 4 C). 
These aberrantly activated and increased macrophages may 
have an important progressive role for the colon tumors in 
SOCS1−/−Tg mice.
We then investigated iNOS and COX-2 expression in 
response to IFNγ in peritoneal macrophages and mouse 
  embryonic fi  broblasts (MEFs). As expected, SOCS1-defi  cient 
macrophages and MEFs produced COX-2 and iNOS more 
extensively than SOCS1+/+ cells (Fig. 4 D). These data dem-
onstrate the importance of SOCS1 in IFNγ signal regulation 
not only for epithelial cells but also for the stromal cells, in-
cluding macrophages and fi  broblasts in tumor formation.
In this study, we have shown that SOCS1 is one of the 
candidate tumor suppressor genes for infl  ammation-associ-
ated colon cancer. SOCS1 defi  ciency enhanced STAT3, 
NF-κB, and STAT1 activations which induced apoptosis 
  inhibitors, cell cycle regulators, COX-2, and iNOS (Fig. 5). 
COX-2 expression in tumor-infi  ltrating macrophages is an 
early event in colon carcinogenesis, and inhibition of COX-2 
activity represents an eff  ective chemopreventive strategy (24). 
In addition, there is a positive correlation between iNOS 
  activity and G:C to A:T mutations at 5-methylcytosine sites 
in p53 gene in human colon tumors (25). Thus, high expres-
sion of iNOS may be one reason for high frequency of p53 
mutation in SOCS1−/−Tg colon tumors. The importance of 
altered p53 expression in the development of colitis-related 
colonic neoplasms in human has been reported (26, 27). 
The features of the colon cancers in SOCS1−/−Tg mice are 
similar to those of human colitis-associated colon cancer. 
These unique features of SOCS1−/−Tg mice will provide 1396  COLORECTAL TUMORIGENESIS IN SOCS1−/− MIC | Hanada et al. 
novel insights into the pathogenesis of infl   ammation-
  associated cancers.
We believe that macrophage activation is important for 
the development of colitis and tumor. Colitis in SOCS1-
defi  ceint mice was dependent on intestinal fl  ora because we 
observed almost no colitis in SOCS1−/−TCRα−/− mice 
when antibiotics were included in the drinking water (un-
published data). Therefore, macrophage activation by both 
TLR and IFNγ must play an important role in the tumor de-
velopment. This also explains why tumorigenesis is restricted 
in the colon of SOCS1−/−Tg mice.
MATERIALS AND METHODS
Mice. SOCS1−/−, IFNγ−/−SOCS1−/−, and SOCS1−/−Tg mice were 
  described previously (15). All experiments using these mice were approved 
by and performed according to the guidelines of the animal ethics committee 
of Kyushu University, Fukuoka, Japan.
Histopathological and immunohistochemical studies. Colons were 
isolated and opened longitudinally to inspect for mucosal tumors. Tissue sam-
ples were fi  xed in 10% buff  ered formalin and embedded in paraffi   n. Sections 
(5-μm-thick) were cut and stained with hematoxylin and eosin (HE). The 
severity of colitis was determined by the histological scoring system as de-
scribed previously (8). For immunohistochemistry, paraffi   n-embedded sec-
tions were dehydrated and then microwaved in 10 mM citrate buff  er (pH 6.0) 
twice for 5 min each. Then, the sections were incubated with the following 
antibodies: anti–β-catenin (clone 14; BD Transduction Laboratories; 1:200 
dilution), anti-p53 (CM-1 and CM-5; Novocastra Laboratories, Ltd.; 1:1,000 
dilution), anti–phospho-STAT1 (Tyr701; Cell Signaling; 1:100 dilution), 
anti–phospho-STAT3 (Tyr705; Cell Signaling; 1:100 dilution), anti–COX-2 
(Cayman Chemical; 1:200 dilution), anti-iNOS (Santa Cruz Biotechnology, 
Inc.; 1:50 dilution), anti-TNFα (MP6-XT22; 1:100 dilution), anti-PCNA 
(PC10; DakoCytomation; 1:100 dilution), and anti-F4/80 (CI:A3-1; Serotec; 
1:50 dilution). ENVISION+ System-HRP (DakoCytomation) was used for 
detection. All sections were counterstained with hematoxylin. TUNEL stain-
ing was performed using an ApoTag Peroxidase In Situ Apoptosis Detection 
kit (CHEMICON) according to the manufacturer’s instructions.
In vivo monoclonal antibody treatment. For in vivo mAb treatment, 
rat anti–mouse TNFα mAb (MP6-XT22) and anti–IFNγ mAb (R4.6A2) 
were used (8). Rat IgG (Zymed Laboratories) was used as the control anti-
body. The mice were intraperitoneally injected with anti-IFNγ mAb or 
anti-TNFα mAb or the control antibody (200 μg/mouse) twice a week 
from the beginning of 2 to 6 mo of age. The mice were killed and then were 
examined to determine the severity of colitis and tumor development.
Statistical analysis. For statistical analysis, we used Student’s t test. A 95% 
confi  dence limit was taken to be signifi  cant and defi  ned as P < 0.05.
Online supplemental material. Fig. S1 shows infl  ammatory cytokine lev-
els determined by real time RT-PCR. Fig. S2 shows localization of TNFα 
and pERK. Online supplemental material is available at http://www.jem.
org/cgi/content/full/jem.20060436/DC1.
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